BIO Stock Overview
Biofarm S.A. manufactures and sells medicines primarily in Romania.
Price History & Performance
|Historical stock prices|
|Current Share Price||RON0.79|
|52 Week High||RON0.85|
|52 Week Low||RON0.46|
|1 Month Change||-4.34%|
|3 Month Change||26.43%|
|1 Year Change||68.94%|
|3 Year Change||136.31%|
|5 Year Change||192.99%|
|Change since IPO||105.28%|
Recent News & Updates
Is Biofarm S.A.'s (BVB:BIO) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Biofarm's (BVB:BIO) stock is up by a considerable 40% over the past three months. Given that the market rewards strong...
Is There More To The Story Than Biofarm's (BVB:BIO) Earnings Growth?
Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability...
Shareholders Of Biofarm (BVB:BIO) Must Be Happy With Their 140% Total Return
When we invest, we're generally looking for stocks that outperform the market average. And the truth is, you can make...
|BIO||RO Pharmaceuticals||RO Market|
Return vs Industry: BIO exceeded the RO Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: BIO exceeded the RO Market which returned 22.7% over the past year.
|BIO Average Weekly Movement||6.6%|
|Pharmaceuticals Industry Average Movement||5.7%|
|Market Average Movement||4.4%|
|10% most volatile stocks in RO Market||6.8%|
|10% least volatile stocks in RO Market||2.5%|
Stable Share Price: BIO is more volatile than 75% of RO stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: BIO's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of RO stocks.
About the Company
Biofarm S.A. manufactures and sells medicines primarily in Romania. It offers a portfolio of products covering therapeutic areas, such as anti-allergic, cardiovascular and circulatory, dermatological, digestive and metabolic, endocrine, genitourinary, multivitamins, ophthalmologic, musculoskeletal, respiratory and ENT, and neurological. The company provides prescription and non-prescription medicines, food supplements, medical devices, cosmetics, and other products.
Biofarm Fundamentals Summary
|BIO fundamental statistics|
Is BIO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BIO income statement (TTM)|
|Cost of Revenue||RON41.76m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.064|
|Net Profit Margin||26.32%|
How did BIO perform over the long term?See historical performance and comparison
2.8%Current Dividend Yield
Is Biofarm undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BIO (RON0.79) is trading below our estimate of fair value (RON1.1)
Significantly Below Fair Value: BIO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BIO is good value based on its PE Ratio (12.3x) compared to the European Pharmaceuticals industry average (26.3x).
PE vs Market: BIO is good value based on its PE Ratio (12.3x) compared to the RO market (12.6x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BIO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BIO is good value based on its PB Ratio (2.4x) compared to the XE Pharmaceuticals industry average (2.9x).
How is Biofarm forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biofarm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Biofarm performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BIO has high quality earnings.
Growing Profit Margin: BIO's current net profit margins (26.3%) are lower than last year (26.3%).
Past Earnings Growth Analysis
Earnings Trend: BIO's earnings have grown by 15% per year over the past 5 years.
Accelerating Growth: BIO's earnings growth over the past year (12.9%) is below its 5-year average (15% per year).
Earnings vs Industry: BIO earnings growth over the past year (12.9%) exceeded the Pharmaceuticals industry 11.9%.
Return on Equity
High ROE: BIO's Return on Equity (19.5%) is considered low.
How is Biofarm's financial position?
Financial Position Analysis
Short Term Liabilities: BIO's short term assets (RON229.9M) exceed its short term liabilities (RON66.4M).
Long Term Liabilities: BIO's short term assets (RON229.9M) exceed its long term liabilities (RON620.9K).
Debt to Equity History and Analysis
Debt Level: BIO is debt free.
Reducing Debt: BIO has not had any debt for past 5 years.
Debt Coverage: BIO has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: BIO has no debt, therefore coverage of interest payments is not a concern.
What is Biofarm current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BIO's dividend (2.77%) is higher than the bottom 25% of dividend payers in the RO market (2.76%).
High Dividend: BIO's dividend (2.77%) is low compared to the top 25% of dividend payers in the RO market (5.82%).
Stability and Growth of Payments
Stable Dividend: BIO's dividends per share have been stable in the past 10 years.
Growing Dividend: BIO's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (34.1%), BIO's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Vicol Constantin (47 yo)
Vicol Catalin Constantin serves as Director and General Manager at Biofarm S.A.
Experienced Management: BIO's management team is considered experienced (3.1 years average tenure).
Experienced Board: BIO's board of directors are considered experienced (4.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Biofarm S.A.'s employee growth, exchange listings and data sources
- Name: Biofarm S.A.
- Ticker: BIO
- Exchange: BVB
- Founded: 1921
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: RON782.382m
- Shares outstanding: 985.37m
- Website: https://www.biofarm.ro
Number of Employees
- Biofarm S.A.
- 99 Logofatul Tautu Street
- Sector 3
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/26 22:25|
|End of Day Share Price||2022/01/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.